A new high-throughput approach targets MDM2 as a way to overcome radiation resistance in uveal melanoma. The work is designed to identify and validate combinations or mechanisms that can sensitize tumors to radiation, a major obstacle in ocular oncology. By using a scalable screening strategy directed at the MDM2 axis, the study aims to speed up discovery of therapeutic candidates and potentially improve the way resistance mechanisms are addressed in preclinical models. The approach could support more efficient translation of MDM2 pathway interventions into further study. For teams working in radiation-refractory cancers, the central point is the workflow’s focus on high-throughput characterization tied to a clinically relevant resistance problem. The next step would be outcome validation in additional models and, ultimately, early-phase studies if candidates emerge from the screen.